About the Company
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ISR News
Perspective Therapeutics Inc (CATX) Stock Experiences 15.67% Monthly Change
During the last 5 trading sessions, CATX fell by -0.65%, which changed the moving average for the period of 200-days by +137.50% in comparison to the 20-day moving average, which settled at $1.4165.
The -13.88% Decline of Perspective Therapeutics Inc’s (CATX) Stock in the Past Quarter
CATX stock has gone up by 0.67%, with a monthly gain of 40.19% and a quarterly surge of 160.87%. The volatility ratio for the week is 10.46%, and the volatility levels for the last 30 days are 10.36% ...
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical ...
Perspective Therapeutics Inc CATX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers ...
Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results
Warning! GuruFocus has detected 7 Warning Signs with CATX. Perspective Therapeutics Inc (CATX), a pioneering radiopharmaceutical company focused on advanced cancer treatments, announced its fiscal ...
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical ...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers ...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
Perspective Therapeutics, Inc. and Subsidiaries Consolidated Statements of Operations (Dollars and shares in thousands, except for per share amounts) Year ended December 31, 2023 2022 (unaudited) ...
Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
Perspective Therapeutics, Inc. and Subsidiaries Consolidated Balance Sheets (In thousands, except shares) December 31, December 31, 2023 2022 ASSETS Current assets: Cash and cash equivalents ...
Loading the latest forecasts...